DiaCarta, Inc.

DiaCarta, Inc. is a biotechnology startup that has been shaping the future of precision molecular diagnostics since its inception in 2011. The company's slogan, "Redefining Precision Molecular Diagnostics through Cancer Gene Mutation Detection," reflects its mission to revolutionize cancer diagnosis, therapy identification, and prognosis monitoring. DiaCarta's focus on translational genomics and personalized diagnostics is evident in its provision of ultra-sensitive detection tools. This emphasis aligns with the global goal of impacting healthcare treatment plans and individuals' well-being. In 2018, DiaCarta secured a significant $45.00M Series B investment, an indicator of investor confidence in the company's potential and vision. Noteworthy entities such as Fortune Fountain Capital and Good Health Capital (GHC) contributed to this landmark investment. DiaCarta's headquarters is located in the United States, positioning the company within the heart of innovation and advancement in the biotechnology industry. With its cutting-edge technologies and unwavering dedication to impacting healthcare, DiaCarta is poised to solidify its position as a leader in the field of precision molecular diagnostics. For further information, individuals can visit DiaCarta's website at http://www.diacarta.com.